Sorafenib (NEXAVAR) 200 MG Tablet

$14,022.00

Nexavar 200 MG Tablet is indicated for the treatment of patients with advanced or metastatic RCC, offering a valuable therapeutic option for individuals who have progressed on prior systemic therapy. Sorafenib’s targeted action against VEGFRs and other kinases plays a crucial role in slowing tumor growth and improving patient outcomes in this challenging disease

Tag:

Sorafenib NEXAVAR

Description

Nexavar 200 MG Tablet contains sorafenib as its active pharmaceutical ingredient, offering a breakthrough treatment option for patients battling advanced or metastatic renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), two of the most prevalent and challenging forms of cancer. Sorafenib is a multikinase inhibitor that targets various signaling pathways involved in tumor growth and angiogenesis, representing a pivotal advancement in the management of these aggressive malignancies.

Key Features:

Multikinase Inhibitor: Sorafenib acts as a potent inhibitor of multiple protein kinases, including RAF kinase, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and receptor tyrosine kinases (RTKs) such as c-KIT and FLT-3. By targeting these key signaling pathways, sorafenib inhibits tumor cell proliferation and angiogenesis, thereby impeding cancer progression.
Treatment of Renal Cell Carcinoma (RCC): Nexavar 200 MG Tablet is indicated for the treatment of patients with advanced or metastatic RCC, offering a valuable therapeutic option for individuals who have progressed on prior systemic therapy. Sorafenib’s targeted action against VEGFRs and other kinases plays a crucial role in slowing tumor growth and improving patient outcomes in this challenging disease